Cefepime-enmetazobactam tops piperacillin-tazobactam for complicated UTI, acute pyelonephritis
18 Nov 2020
byAudrey Abella
The investigational combination drug comprising the fourth-generation cephalosporin cefepime and the novel, potent extended-spectrum β-lactamase (ESBL) inhibitor enmetazobactam (FPE) demonstrated superiority to the piperacillin-tazobactam (PTZ) regimen in patients with complicated* urinary tract infection/acute pyelonephritis (cUTI/AP) caused by ESBL-producing Enterobacterales, according to the results of the ALLIUM trial.
Cefepime-enmetazobactam tops piperacillin-tazobactam for complicated UTI, acute pyelonephritis
18 Nov 2020